Chimeric Antigen Receptor T-cell therapy (CAR-T) is an immunocellular therapy. This novel class of medicines, often referred to as Advanced Therapy Medicinal Products - ATMPs, are new and complex biological treatments. ATMPs can potentially transform the lives of patients who have treatment resistant blood cancers. As with most complex therapies, there can be serious and sometimes life-threatening complications to this novel and advanced technology. Every healthcare professional in contact with patients undergoing this treatment, both now and in the future, should be aware of immunocellular/ATMP therapy.
King’s College Hospital is the first site in the UK to prescribe and administer licenced
CAR-T therapy to adult lymphoma patients.
This exciting event, jointly hosted by RPS and King's College Hospital, will equip you with knowledge, skills and confidence to be able to understand CAR-T / ATMP therapy and its place in clinical medicine, now and in the future.
By attending this event you will:
- Appreciate the clinical applications of ATMPs from a diverse range of perspectives and clinical experience;
- Understand what best practice should (ideally) look like when prescribing and handling ATMPs;
- Learn of the adverse effects of CAR-T and how to treat;
- Consider new roles and opportunities for pharmacists and qualified persons;
- Apply theory to practice with real life case study discussions;
- Provide essential information to patients regarding funding and eligibility for ATMPs;
- Have the opportunity to meet a UK ATMPs expert multidisciplinary team.
Who should attend?
The event is relevant for all healthcare professionals coming into contact with ATMPs or encountering patients with treatment resistant cancer (especially lymphomas and leukaemia’s). Including oncology, haematology, critical care, community and clinical settings.
Registration fee includes:
- Access to all plenary sessions;
- Digital copies of all presentations to support future learning;
- Refreshments and lunch.
Invest one day to meet and put your questions to the experts, who are prescribing, reviewing and administering the first ATMP: CAR-T.